EPZM insider filings
Epizyme, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2022-08-16. Screen EPZM transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for EPZM between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Epizyme, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2022-08-16 | 4 | Giordano Michael F — Director | Disposition to issuer (D): 8,060 · Disposition to issuer (D): 8,994 | EDGAR |
| 2022-08-16 | 4 | Richon Victoria — Director | Disposition to issuer (D): 13,614 · Disposition to issuer (D): 8,994 | EDGAR |
| 2022-08-16 | 4 | BEVERIDGE, ROY A — Director | Disposition to issuer (D): 20,341 · Disposition to issuer (D): 25,696 | EDGAR |
| 2022-08-16 | 4 | Agarwal Shefali | Disposition to issuer (D): 179,247 · Disposition to issuer (D): 107,292 | EDGAR |
| 2022-08-16 | 4 | Korn Jerald — Chief Operating Officer | Holdings only — no transactions reported | EDGAR |
| 2022-08-16 | 4 | Beaulieu Joseph — See Remarks | Disposition to issuer (D): 30,181 · Disposition to issuer (D): 21,895 | EDGAR |
| 2022-08-16 | 4 | Kutok Jeffery — Chief Scientific Officer | Disposition to issuer (D): 39,046 · Disposition to issuer (D): 81,021 | EDGAR |
| 2022-08-16 | 4 | Stuckley Carol — Director | Disposition to issuer (D): 25,696 | EDGAR |
| 2022-08-16 | 4 | Bogle Grant C. — President and CEO, Director | Disposition to issuer (D): 84,170 · Disposition to issuer (D): 175,000 | EDGAR |
| 2022-08-16 | 4 | Legorreta Pablo G. — Director, 10% owner RP Management, LLC — Director, 10% owner RPI Finance Trust — Director, 10% owner Royalty Pharma Investments 2019 ICAV — Director, 10% owner | Code (U): 31,933,334 · Disposition to issuer (D): 8,060 (derivative) @ $0 · Disposition to issuer (D): 8,994 (derivative) @ $0 | EDGAR |
| 2022-08-16 | 4 | Conroy Kevin T — Director | Disposition to issuer (D): 53,324 · Disposition to issuer (D): 8,994 | EDGAR |
| 2022-08-16 | 4 | MOTT DAVID M — Director | Code (U): 215,494 · Disposition to issuer (D): 8,994 · Code (U): 106,959 | EDGAR |
| 2022-08-16 | 4 | BATE KENNETH — Director | Disposition to issuer (D): 8,060 · Disposition to issuer (D): 8,994 | EDGAR |
| 2022-08-16 | 4 | GOLDFISCHER CARL — Director | Disposition to issuer (D): 13,060 · Disposition to issuer (D): 8,994 · Disposition to issuer (D): 3,380,951 | EDGAR |
| 2022-08-11 | 4 | Bogle Grant C. — See Remarks, Director | Option exercise (M): 800,000 @ $1.39 · Tax withholding (F): 746,307 @ $1.39 · Option exercise (M): 417,500 @ $1.41 · Tax withholding (F): 395,083 @ $1.41 · Option exercise (M): 800,000 (derivative) @ $0 · Option exercise (M): 417,500 (derivative) @ $0 | EDGAR |
| 2022-08-11 | 4 | Agarwal Shefali | Option exercise (M): 56,527 @ $1.39 · Option exercise (M): 43,473 @ $1.39 · Option exercise (M): 400,000 @ $1.39 · Tax withholding (F): 373,154 @ $1.39 · Option exercise (M): 56,527 (derivative) @ $0 · Option exercise (M): 43,473 (derivative) @ $0 · +1 more | EDGAR |
| 2022-08-11 | 4 | Beaulieu Joseph — See Remarks | Option exercise (M): 300,000 @ $1.39 · Tax withholding (F): 279,864 @ $1.39 · Option exercise (M): 300,000 (derivative) @ $0 | EDGAR |
| 2022-08-11 | 4 | Kutok Jeffery — Chief Scientific Officer | Option exercise (M): 380,000 @ $1.39 · Tax withholding (F): 354,496 @ $1.39 · Option exercise (M): 380,000 (derivative) @ $0 | EDGAR |
| 2022-07-05 | 4 | BEVERIDGE, ROY A — Director | Grant/award (A): 8,928 @ $1.47 | EDGAR |
| 2022-07-05 | 4 | Conroy Kevin T — Director | Grant/award (A): 10,204 @ $1.47 | EDGAR |
| 2022-07-05 | 4 | MOTT DAVID M — Director | Grant/award (A): 16,156 @ $1.47 | EDGAR |
| 2022-05-19 | 4 | Richon Victoria — Director | Grant/award (A): 8,994 @ $0 · Grant/award (A): 41,006 (derivative) @ $0 | EDGAR |
| 2022-05-19 | 4 | Stuckley Carol — Director | Grant/award (A): 8,994 @ $0 · Grant/award (A): 41,006 (derivative) @ $0 | EDGAR |
| 2022-05-19 | 4 | Giordano Michael F — Director | Grant/award (A): 8,994 @ $0 · Grant/award (A): 41,006 (derivative) @ $0 | EDGAR |
| 2022-05-19 | 4 | BEVERIDGE, ROY A — Director | Grant/award (A): 8,994 @ $0 · Grant/award (A): 41,006 (derivative) @ $0 | EDGAR |
| 2022-05-19 | 4 | Legorreta Pablo G. — Director, 10% owner RP Management, LLC — Director, 10% owner RPI Finance Trust — Director, 10% owner Royalty Pharma Investments 2019 ICAV — Director, 10% owner | Grant/award (A): 41,006 (derivative) @ $0.56 · Grant/award (A): 8,994 (derivative) @ $0 | EDGAR |
| 2022-05-19 | 4 | Conroy Kevin T — Director | Grant/award (A): 8,994 @ $0 · Grant/award (A): 41,006 (derivative) @ $0 | EDGAR |
| 2022-05-19 | 4 | MOTT DAVID M — Director | Grant/award (A): 8,994 @ $0 · Grant/award (A): 41,006 (derivative) @ $0 | EDGAR |
| 2022-05-19 | 4 | BATE KENNETH — Director | Grant/award (A): 8,994 @ $0 · Grant/award (A): 41,006 (derivative) @ $0 | EDGAR |
| 2022-05-19 | 4 | GOLDFISCHER CARL — Director | Grant/award (A): 8,994 @ $0 · Grant/award (A): 41,006 (derivative) @ $0 | EDGAR |
| 2022-04-13 | 4 | Kutok Jeffery — Chief Scientific Officer | Sale (S): 2,741 @ $0.90 | EDGAR |
| 2022-04-04 | 4 | Korn Jerald — Chief Operating Officer | Grant/award (A): 800,000 (derivative) @ $0 | EDGAR |
| 2022-04-01 | 4 | BEVERIDGE, ROY A — Director | Grant/award (A): 11,413 @ $1.15 | EDGAR |
| 2022-04-01 | 4 | Conroy Kevin T — Director | Grant/award (A): 13,043 @ $1.15 | EDGAR |
| 2022-04-01 | 4 | MOTT DAVID M — Director | Grant/award (A): 20,653 @ $1.15 | EDGAR |
| 2022-03-21 | 4 | Bogle Grant C. — See Remarks, Director | Grant/award (A): 800,000 (derivative) @ $0 | EDGAR |
| 2022-03-21 | 4 | Beaulieu Joseph — See Remarks | Grant/award (A): 2,331 @ $1.27 · Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2022-03-21 | 4 | Kutok Jeffery — Chief Scientific Officer | Grant/award (A): 380,000 (derivative) @ $0 | EDGAR |
| 2022-03-21 | 4 | Agarwal Shefali — See Remarks | Grant/award (A): 2,331 @ $1.27 · Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2022-02-09 | 4 | Beaulieu Joseph — Corporate Controller | Sale (S): 222 @ $1.50 | EDGAR |
| 2022-02-09 | 4 | Agarwal Shefali — See Remarks | Sale (S): 1,058 @ $1.50 | EDGAR |
| 2022-02-04 | 4 | Agarwal Shefali — See Remarks | Sale (S): 2,639 @ $1.37 | EDGAR |
| 2022-02-04 | 4 | Bogle Grant C. — See Remarks, Director | Grant/award (A): 87,500 @ $0 · Grant/award (A): 417,500 (derivative) @ $0 | EDGAR |
| 2022-02-04 | 4 | Kutok Jeffery — Chief Scientific Officer | Sale (S): 2,556 @ $1.37 | EDGAR |
| 2022-02-04 | 4 | Beaulieu Joseph — Corporate Controller | Sale (S): 687 @ $1.37 | EDGAR |
| 2022-02-01 | 4 | Legorreta Pablo G. — Director, 10% owner RP Management, LLC — 10% owner RPI Finance Trust — 10% owner | Purchase (P): 22,666,667 @ $1.50 | EDGAR |
| 2022-01-28 | 4 | Agarwal Shefali — See Remarks | Sale (S): 2,922 @ $2.02 | EDGAR |
| 2022-01-04 | 4 | Conroy Kevin T — Director | Grant/award (A): 6,000 @ $2.50 | EDGAR |
| 2022-01-04 | 4 | MOTT DAVID M — Director | Grant/award (A): 9,500 @ $2.50 | EDGAR |
| 2021-12-07 | 4 | Agarwal Shefali — See Remarks | Sale (S): 1,780 @ $2.93 | EDGAR |
Recent 8-K events — Epizyme, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2022-08-12 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-08-09 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-06-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-05-24 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2022-05-19 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-05-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-04-06 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2022-03-15 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-03-01 | 8-K | 2.02 — Results of Operations and Financial Condition ? 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-01-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=EPZM returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs